FDA
-
-
-
-
-
-
-
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Dyne reports heart and lung function improvements in DMD trial
-
-
-
-
-
-
-
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group
-
-
-
-
-
-
-
Dyne Therapeutics reports one-year data for DM1 treatment trial
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)
-
-
-
-
-
-
-
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
-
322,212 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

